Literature DB >> 33484770

The changing context of hepatitis D.

Mario Rizzetto1, Saeed Hamid2, Franco Negro3.   

Abstract

The global epidemiology of hepatitis D is changing with the widespread implementation of vaccination against hepatitis B. In high-income countries that achieved optimal control of HBV, the epidemiology of hepatitis D is dual, consisting of an ageing cohort of domestic patients with advanced liver fibrosis who represent the end stage of the natural history of HDV, and of a younger generation of immigrants from endemic countries who account for the majority of new infections. As observed in Europe in the 1980s, the distinctive clinical characteristic of chronic hepatitis D in endemic countries is the accelerated progression to cirrhosis and hepatocellular carcinoma. Despite some recent progress, the therapeutic management of HDV remains unsatisfactory, as most patients are not cured of HDV with currently available medicines. This review article describes the current epidemiology and clinical features of chronic hepatitis D, based on the literature published in the last 10 years.
Copyright © 2021. Published by Elsevier B.V.

Entities:  

Keywords:  antiviral therapy; cirrhosis; hepatitis D; hepatocellular carcinoma; viral hepatitis epidemiology

Mesh:

Substances:

Year:  2021        PMID: 33484770     DOI: 10.1016/j.jhep.2021.01.014

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  19 in total

Review 1.  Recent breakthroughs in the treatment of chronic hepatitis Delta.

Authors:  Giuseppina Brancaccio; Laura Gaeta; Alessandro Vitale; Giovanni B Gaeta
Journal:  Infez Med       Date:  2022-06-01

Review 2.  Novel Pegylated Interferon for the Treatment of Chronic Viral Hepatitis.

Authors:  Yi-Wen Huang; Albert Qin; Chan-Yen Tsai; Pei-Jer Chen
Journal:  Viruses       Date:  2022-05-25       Impact factor: 5.818

Review 3.  HDV Pathogenesis: Unravelling Ariadne's Thread.

Authors:  Eirini D Tseligka; Sophie Clément; Francesco Negro
Journal:  Viruses       Date:  2021-04-28       Impact factor: 5.048

Review 4.  Endpoints and New Options for Treatment of Chronic Hepatitis D.

Authors:  Anna S Lok; Francesco Negro; Tarik Asselah; Patrizia Farci; Mario Rizzetto
Journal:  Hepatology       Date:  2021-09-16       Impact factor: 17.298

5.  Forty-Five Years after the Discovery of the Hepatitis D Virus: Where Do We Stand?

Authors:  Mario Rizzetto; Tommaso Stroffolini
Journal:  Viruses       Date:  2021-03-26       Impact factor: 5.048

6.  Hepatitis D virus (HDV) prevalence in Austria is low but causes considerable morbidity due to fast progression to cirrhosis.

Authors:  Mathias Jachs; Teresa Binter; Caroline Schmidbauer; Lukas Hartl; Michael Strasser; Hermann Laferl; Stephanie Hametner-Schreil; Alexander Lindorfer; Kristina Dax; Rudolf E Stauber; Harald H Kessler; Sebastian Bernhofer; Andreas Maieron; Lorin Loacker; Simona Bota; Isabel Santonja; Petra Munda; Mattias Mandorfer; Markus Peck-Radosavljevic; Heidemarie Holzmann; Michael Gschwantler; Heinz Zoller; Peter Ferenci; Thomas Reiberger
Journal:  United European Gastroenterol J       Date:  2021-12-07       Impact factor: 4.623

Review 7.  Hepatitis D Virus and Hepatocellular Carcinoma.

Authors:  Patrizia Farci; Grazia Anna Niro; Fausto Zamboni; Giacomo Diaz
Journal:  Viruses       Date:  2021-05-04       Impact factor: 5.048

Review 8.  Innate immunity in hepatitis B and D virus infection: consequences for viral persistence, inflammation, and T cell recognition.

Authors:  Maura Dandri; Antonio Bertoletti; Marc Lütgehetmann
Journal:  Semin Immunopathol       Date:  2021-05-21       Impact factor: 9.623

9.  Liver Transplantation for Hepatitis D Virus in the United States: A UNOS Study on Outcomes in the MELD Era.

Authors:  Tatyana Kushner; Ben L Da; Aryana Chan; Douglas Dieterich; Keith Sigel; Behnam Saberi
Journal:  Transplant Direct       Date:  2021-12-17

Review 10.  Hepatitis D virus in 2021: virology, immunology and new treatment approaches for a difficult-to-treat disease.

Authors:  Stephan Urban; Christoph Neumann-Haefelin; Pietro Lampertico
Journal:  Gut       Date:  2021-06-08       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.